Peckham M J, Horwich A, Hendry W F
Br J Cancer. 1985 Jul;52(1):7-13. doi: 10.1038/bjc.1985.141.
Between 1978 and 1983, 44 patients with advanced seminoma were treated with cis-platinum-based combination chemotherapy (39 patients) or with carboplatin (JM8), as a single agent (5 patients). Of the total group, 40 (90%) are alive and disease free. Two of the 4 patients who died relapsed as non-seminomatous germ-cell tumours. Results in previously untreated patients indicate that tumour volume is less important as a prognostic factor than in non-seminomas. Residual masses were present in almost 80% of patients 1 month after chemotherapy; such masses regress slowly and surgery is not indicated. Elective radiotherapy after chemotherapy appears to be inessential since relapse rates are comparable in irradiated (1/15) and unirradiated patients (1/16). Pretreatment serum HCG concentrations did not influence the outcome of chemotherapy. Preliminary results with JM8 suggest that it is an active single agent in the treatment of seminoma.
1978年至1983年间，44例晚期精原细胞瘤患者接受了以顺铂为基础的联合化疗（39例患者）或卡铂（JM8）单药治疗（5例患者）。在整个研究组中，40例（90%）存活且无疾病。死亡的4例患者中有2例复发为非精原细胞瘤性生殖细胞肿瘤。先前未接受治疗患者的结果表明，与非精原细胞瘤相比，肿瘤体积作为预后因素的重要性较低。化疗1个月后，几乎80%的患者存在残留肿块；这些肿块消退缓慢，不建议进行手术。化疗后选择性放疗似乎并非必要，因为接受放疗的患者（1/15）和未接受放疗的患者（1/16）的复发率相当。化疗前血清HCG浓度不影响化疗结果。JM8的初步结果表明，它是治疗精原细胞瘤的一种有效的单药。
